Do analysts prefer SCNI or XAGE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SCNI or XAGE more profitable?

Scinai Immunotherapeutics has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Longevity Health -682.67% N/A -261.90%

Do analysts prefer XAGE or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, XAGE or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Longevity Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Longevity Health $1.05M 0.26 -$10.37M -$3.49 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is XAGE or BDRX more profitable?

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Company Net Margins Return on Equity Return on Assets Longevity Health -682.67% N/A -261.90% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts prefer XAGE or BNBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Applied Dna Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Longevity Health (XAGE) Competitors

$0.16 +0.00 (+0.06%)

As of 09/25/2026 02:41 PM Eastern

Compare

XAGE vs. SCNI, BDRX, BNBX, ZVSA, and SQZ

Should you buy Longevity Health stock or one of its competitors? Longevity Health's main competitors and comparable companies include Scinai Immunotherapeutics (SCNI), Biodexa Pharmaceuticals (BDRX), Applied Dna Sciences (BNBX), ZyVersa Therapeutics (ZVSA), and SQZ Biotechnologies (SQZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Longevity Health compare to Scinai Immunotherapeutics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Longevity Health (NASDAQ:XAGE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Scinai Immunotherapeutics has higher revenue and earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.84	-$8.31M	-$95.34	N/A
Longevity Health	$1.05M	0.26	-$10.37M	-$3.49	N/A

Scinai Immunotherapeutics has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Longevity Health	-682.67%	N/A	-261.90%

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 24.2% of Longevity Health shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 29.0% of Longevity Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scinai Immunotherapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Longevity Health has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

In the previous week, Scinai Immunotherapeutics had 5 more articles in the media than Longevity Health. MarketBeat recorded 5 mentions for Scinai Immunotherapeutics and 0 mentions for Longevity Health. Scinai Immunotherapeutics' average media sentiment score of 0.35 beat Longevity Health's score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Longevity Health	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Scinai Immunotherapeutics beats Longevity Health on 12 of the 13 factors compared between the two stocks.

How does Longevity Health compare to Biodexa Pharmaceuticals?

Longevity Health (NASDAQ:XAGE) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Longevity Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.26	-$10.37M	-$3.49	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

In the previous week, Biodexa Pharmaceuticals had 3 more articles in the media than Longevity Health. MarketBeat recorded 3 mentions for Biodexa Pharmaceuticals and 0 mentions for Longevity Health. Biodexa Pharmaceuticals' average media sentiment score of 0.23 beat Longevity Health's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Longevity Health	Neutral
Biodexa Pharmaceuticals	Neutral

Longevity Health has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Biodexa Pharmaceuticals	N/A	N/A	N/A

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Biodexa Pharmaceuticals beats Longevity Health on 7 of the 10 factors compared between the two stocks.

How does Longevity Health compare to Applied Dna Sciences?

Longevity Health (NASDAQ:XAGE) and Applied Dna Sciences (NASDAQ:BNBX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Longevity Health has higher earnings, but lower revenue than Applied Dna Sciences. Longevity Health is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.26	-$10.37M	-$3.49	N/A
Applied Dna Sciences	$2.09M	0.40	-$15.16M	-$3.33	N/A

Longevity Health has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Applied Dna Sciences has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Applied Dna Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Longevity Health has a net margin of -682.67% compared to Applied Dna Sciences' net margin of -1,647.25%. Longevity Health's return on equity of 0.00% beat Applied Dna Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 22.2% of Applied Dna Sciences shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by company insiders. Comparatively, 6.1% of Applied Dna Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Applied Dna Sciences had 6 more articles in the media than Longevity Health. MarketBeat recorded 6 mentions for Applied Dna Sciences and 0 mentions for Longevity Health. Longevity Health's average media sentiment score of 0.00 equaled Applied Dna Sciences'average media sentiment score.

Company	Overall Sentiment
Longevity Health	Neutral
Applied Dna Sciences	Neutral

Summary

Applied Dna Sciences beats Longevity Health on 7 of the 13 factors compared between the two stocks.

How does Longevity Health compare to ZyVersa Therapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Longevity Health (NASDAQ:XAGE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

ZyVersa Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Longevity Health has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

ZyVersa Therapeutics has higher earnings, but lower revenue than Longevity Health. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
Longevity Health	$1.05M	0.26	-$10.37M	-$3.49	N/A

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 29.0% of Longevity Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ZyVersa Therapeutics has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Longevity Health	-682.67%	N/A	-261.90%

In the previous week, ZyVersa Therapeutics' average media sentiment score of 0.00 equaled Longevity Health'saverage media sentiment score.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
Longevity Health	Neutral

Summary

ZyVersa Therapeutics and Longevity Health tied by winning 5 of the 10 factors compared between the two stocks.

How does Longevity Health compare to SQZ Biotechnologies?

Longevity Health (NASDAQ:XAGE) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 29.0% of Longevity Health shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Longevity Health has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

SQZ Biotechnologies has a net margin of -369.96% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

In the previous week, Longevity Health's average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company	Overall Sentiment
Longevity Health	Neutral
SQZ Biotechnologies	Neutral

Longevity Health has higher earnings, but lower revenue than SQZ Biotechnologies. Longevity Health is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.26	-$10.37M	-$3.49	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

Summary

SQZ Biotechnologies beats Longevity Health on 7 of the 11 factors compared between the two stocks.

Get Longevity Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XAGE vs. The Competition

Export

Metric	Longevity Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$278K	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.04%
P/E Ratio	-0.04	14.15	275.82	25.78
Price / Sales	0.26	1,424.97	646.72	93.11
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	-0.02	15.28	10.44	6.30
Net Income	-$10.37M	-$22.90M	$3.51B	$360.35M
7 Day Performance	-8.18%	-2.94%	-1.31%	-0.23%
1 Month Performance	-30.00%	-8.80%	-4.61%	-4.16%
1 Year Performance	-78.91%	28.99%	15.01%	4.58%

Longevity Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XAGE Longevity Health	N/A	$0.16 +0.1%	N/A	-78.9%	$278K	$1.05M	N/A	10
SCNI Scinai Immunotherapeutics	0.4606 of 5 stars	$1.49 -3.4%	N/A	-88.3%	$1.05M	$1.31M	N/A	20	News Coverage Short Interest Increase Gap Down
BDRX Biodexa Pharmaceuticals	0.3614 of 5 stars	$0.97 -27.4%	N/A	-97.9%	$984K	$470K	N/A	20	Short Interest Increase Gap Down
BNBX Applied Dna Sciences	0.0383 of 5 stars	$0.14 +0.5%	N/A	N/A	$843K	$2.09M	N/A	70	News Coverage Gap Down
ZVSA ZyVersa Therapeutics	N/A	$0.10 flat	N/A	-33.0%	$786K	N/A	N/A	2	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XAGE) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longevity Health (XAGE) Competitors

XAGE vs. SCNI, BDRX, BNBX, ZVSA, and SQZ

How does Longevity Health compare to Scinai Immunotherapeutics?

Summary

How does Longevity Health compare to Biodexa Pharmaceuticals?

Summary

How does Longevity Health compare to Applied Dna Sciences?

Summary

How does Longevity Health compare to ZyVersa Therapeutics?

Summary

How does Longevity Health compare to SQZ Biotechnologies?

Summary

Media Sentiment Over Time

XAGE vs. The Competition

Longevity Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longevity Health (XAGE) Competitors

XAGE vs. SCNI, BDRX, BNBX, ZVSA, and SQZ

How does Longevity Health compare to Scinai Immunotherapeutics?

Which has preferable valuation and earnings, SCNI or XAGE?

Is SCNI or XAGE more profitable?

Do insiders and institutionals believe in SCNI or XAGE?

Which has more volatility and risk, SCNI or XAGE?

Does the media favor SCNI or XAGE?

Do analysts prefer SCNI or XAGE?

Summary

How does Longevity Health compare to Biodexa Pharmaceuticals?

Which has better valuation and earnings, XAGE or BDRX?

Does the media refer more to XAGE or BDRX?

Which has more volatility and risk, XAGE or BDRX?

Do analysts prefer XAGE or BDRX?

Is XAGE or BDRX more profitable?

Do institutionals & insiders hold more shares of XAGE or BDRX?

Summary

How does Longevity Health compare to Applied Dna Sciences?

Which has higher valuation and earnings, XAGE or BNBX?

Which has more risk and volatility, XAGE or BNBX?

Do analysts prefer XAGE or BNBX?

Is XAGE or BNBX more profitable?

Do insiders & institutionals have more ownership in XAGE or BNBX?

Does the media favor XAGE or BNBX?

Summary

How does Longevity Health compare to ZyVersa Therapeutics?

Which has more risk and volatility, ZVSA or XAGE?

Which has stronger earnings & valuation, ZVSA or XAGE?

Do insiders and institutionals have more ownership in ZVSA or XAGE?

Is ZVSA or XAGE more profitable?

Does the media prefer ZVSA or XAGE?

Summary

How does Longevity Health compare to SQZ Biotechnologies?

Do institutionals & insiders believe in XAGE or SQZ?

Which has more volatility & risk, XAGE or SQZ?

Is XAGE or SQZ more profitable?

Does the media refer more to XAGE or SQZ?

Which has preferable earnings and valuation, XAGE or SQZ?

Summary

Media Sentiment Over Time

XAGE vs. The Competition

Longevity Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools